Mallinckrodt medical sales rise 15% in third quarter:
This article was originally published in Clinica
Mallinckrodt Medical has reported third-quarter sales of $255.5 million, 15% higher than a year earlier. Mallinckrodt says that its medical division had strong sales in all areas despite continuing downward pressure from healthcare cost reduction efforts. In the first nine months of fiscal 1995 sales rose 12% to $725.7 million. Mallinckrodt's group sales were up 17% to $569.1 million in the third quarter (ended March 31st). Net income improved to $47 million compared with $42.3 million in the same 1994 period.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.